Litcius/Paper detail

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline <i>BRCA1</i> Mutation and High Tumor Mutation Burden: Case Report and Literature Review

Joanne Lundy, Owen McKay, Daniel Croagh, Vinod Ganju

2022JCO Precision Oncology17 citationsDOIOpen Access PDF

Topics & Concepts

PembrolizumabMedicineMutationCancer researchGermlineGermline mutationOlaparibAdenocarcinomaInternal medicineOncologyMutation testingPancreatic ductal adenocarcinomaPancreatic cancerSomatic cellImmunotherapyPancreatic and Hepatic Oncology ResearchPARP inhibition in cancer therapyCancer Genomics and Diagnostics
Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline <i>BRCA1</i> Mutation and High Tumor Mutation Burden: Case Report and Literature Review | Litcius